The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tesofensine results in reduction of caloric intake and weight loss by inhibiting the presynaptic reuptake of dopamine, serotonin, and noradrenaline, and inhibiting the dopamine active transporter (147).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Phelan, S., Cato, R. K., Hesson, L. A., Osei, S. Y., Kaplan, R., & Stunkard, A. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050156 · Cited by 794
Evidence for defective mesolimbic dopamine exocytosis in obesity‐prone rats
Geiger, B. M., Behr, G. G., Frank, L. E., Caldera-Siu, A. D., Beinfeld, M. C., Kokkotou, E. G., & Pothos, E. N. (2008) · The FASEB Journal · doi:10.1096/fj.08-110759 · Cited by 194
Drug Treatment of the Overweight Patient
Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.053 · Cited by 115
Thornton-Jones, Z. D., Kennett, G. A., Benwell, K. R., Revell, D. F., Misra, A., Sellwood, D. M., Vickers, S. P., & Clifton, P. G. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.06.001 · Cited by 83
Central Nervous System Biogenic Amine Targets for Control of Appetite and Energy Expenditure
Nelson, D. L., & Gehlert, D. R. (2006) · Endocrine · doi:10.1385/endo:29:1:49 · Cited by 78
Research works printed but not linked: 30
- Astrup, 2008, Effect of tesofensine on body weight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1906, 10.1016/S0140-6736(08)61525-1 · DOI · Paper page
- Astrup, 2008, Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease, Obesity (Silver Spring Md), 16, 1363, 10.1038/oby.2008.56 · DOI
- Balcioglu, 2000, Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid, Neuropharmacology, 39, 2352, 10.1016/S0028-3908(00)00083-6 · DOI
- Billes, 2007, Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice, Neuropsychopharmacology, 32, 822, 10.1038/sj.npp.1301155 · DOI
- Billes, 2008, Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis, Neuropsychopharmacology, 33, 1287, 10.1038/sj.npp.1301526 · DOI
- Brown, 2001, Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y, Br. J. Pharmacol., 132, 1898, 10.1038/sj.bjp.0704030 · DOI
- Bush, 2006, Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice, Endocrine, 29, 375, 10.1385/ENDO:29:2:375 · DOI
- Connoley, 1999, Thermogenic effects of sibutramine and its metabolites, Br. J. Pharmacol., 126, 1487, 10.1038/sj.bjp.0702446 · DOI
- Fernstrom, 2008, The development of tolerance to drugs that suppress food intake, Pharmacol. Ther., 117, 105, 10.1016/j.pharmthera.2007.09.001 · DOI
- Fisas, 2006, Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats, Br. J. Pharmacol., 148, 973, 10.1038/sj.bjp.0706807 · DOI
- Fulton, 2006, Leptin regulation of the mesoaccumbens dopamine pathway, Neuron, 51, 811, 10.1016/j.neuron.2006.09.006 · DOI · Paper page
- Gary-Bobo, 2007, Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats, Hepatology, 46, 122, 10.1002/hep.21641 · DOI · Paper page
- Glick, 2000, Enantioselective behavioral effects of sibutramine metabolites, Eur. J. Pharmacol., 397, 93, 10.1016/S0014-2999(00)00216-8 · DOI
- Goldstein, 1992, Beneficial health effects of modest weight loss, Int. J. Obes. Relat. Metab. Disord., 16, 397
- Golozoubova, 2006, Locomotion is the major determinant of sibutramine-induced increase in energy expenditure, Pharmacol. Biochem. Behav., 83, 517, 10.1016/j.pbb.2006.03.014 · DOI
- Haslam, 2005, Obesity, Lancet, 366, 1197, 10.1016/S0140-6736(05)67483-1 · DOI · Paper page
- Heal, 1998, A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents, Br. J. Pharmacol., 125, 301, 10.1038/sj.bjp.0702067 · DOI
- Jackson, 1997, Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat, Br. J. Pharmacol., 121, 1613, 10.1038/sj.bjp.0701311 · DOI
- Jackson, 1997, Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat, Br. J. Pharmacol., 121, 1758, 10.1038/sj.bjp.0701312 · DOI
- Kahn, 2000, Obesity and insulin resistance, J. Clin. Invest., 106, 473, 10.1172/JCI10842 · DOI · Paper page
- Lehr, 2008, Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic–pharmacodynamic modelling approach, Br. J. Pharmacol., 153, 164, 10.1038/sj.bjp.0707539 · DOI
- Levin, 2000, Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats, Am. J. Physiol. Regul. Integr. Comp. Physiol., 279, R2222, 10.1152/ajpregu.2000.279.6.R2222 · DOI
- Meguid, 2000, Hypothalamic dopamine and serotonin in the regulation of food intake, Nutrition (Burbank, Los Angeles County, Calif), 16, 843, 10.1016/S0899-9007(00)00449-4 · DOI · Paper page
- Nogueiras, 2008, Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats, Diabetes, 57, 2977, 10.2337/db08-0161 · DOI · Paper page
- Palmiter, 2007, Is dopamine a physiologically relevant mediator of feeding behavior?, Trends Neurosci., 30, 375, 10.1016/j.tins.2007.06.004 · DOI · Paper page
- Paulsen, 2010, Characterization of beta-Cell Mass and Insulin Resistance in Diet-induced Obese and Diet-resistant Rats, Obesity (Silver Spring, Md.), 18, 266, 10.1038/oby.2009.245 · DOI
- Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial, JAMA, 295, 761, 10.1001/jama.295.7.761 · DOI · Paper page
- Tizzano, 2008, The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity, J. Pharmacol. Exp. Ther., 324, 1111, 10.1124/jpet.107.133132 · DOI
- Volkow, 2005, How can drug addiction help us understand obesity?, Nat. Neurosci., 8, 555, 10.1038/nn1452 · DOI · Paper page
- Wortley, 1999, Modulation of sibutramine-induced increases in extracellular noradrenaline concentration in rat frontal cortex and hypothalamus by alpha2-adrenoceptors, Br. J. Pharmacol., 128, 659, 10.1038/sj.bjp.0702859 · DOI
Cited by
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Christoffersen, B. Ø., Sanchez‐Delgado, G., John, L. M., Ryan, D. H., Raun, K., & Ravussin, E. (2022) · Obesity · doi:10.1002/oby.23374 · Cited by 142
“While some also increase energy expenditure in rodents (55), this effect is quite variable in humans.”
BackgroundRandomized controlled trial of Tesomet for weight loss in hypothalamic obesity
Huynh, K., Klose, M., Krogsgaard, K., Drejer, J., Byberg, S., Madsbad, S., Magkos, F., Aharaz, A., Edsberg, B., Tfelt-Hansen, J., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0972 · Cited by 43
Acquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
van Santen, H. M., & Müller, H. L. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf025 · Cited by 21
Metadata
- Authors
- Hansen, H. H., Hansen, G., Tang-Christensen, M., Larsen, P. J., Axel, A. M. D., Raben, A., & Mikkelsen, J. D.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 636
- Issue
- 1-3
- Pages
- 88-95
- ISSN
- 0014-2999
- Cited by
- 35
- References
- 5
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant. https://app.cochat.ai/papers/10.1016/j.ejphar.2010.03.026
- The paper
- Hansen, H. H., Hansen, G., Tang-Christensen, M., Larsen, P. J., Axel, A. M. D., Raben, A., & Mikkelsen, J. D. (2010). The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2010.03.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.